news
Merck to discontinue development of COVID-19 vaccine candidates
Following Phase I results, Merck will discontinue its development of V590 and V591, two COVID-19 vaccine candidates.
List view / Grid view
Clinical Development
Filter the results
article
Incorporating patient-generated health data in safety and efficacy studies
In this article, Alison Bourke, Scientific Director of the Center for Advanced Evidence Generation at IQVIA Health, explores how digitally-connected active and passive data sources are shaping the development of patient-centric treatments and care.
news
Japan has pre-ordered COVID-19 vaccine doses for more than four times its population, says report
Japan has procurement deals with half of the companies leading the COVID-19 vaccine development race, according to GlobalData.
news
Optimising a panel for microbiologic diagnosis of pneumonia
Researchers studying the microbiologic diagnosis of pneumonia have identified ways to optimise a pneumonia panel.
news
Pharma industry employs 5,600 people in Scotland, report says
A new report has shown that the pharmaceutical industry in Scotland employs nine percent more people now than in 2018.
news
Baricitinib and remdesivir reduce time to recovery in COVID-19 patients
A clinical trial in hospitalised COVID-19 patients has demonstrated that baricitinib and remdesivir reduce time to recovery.
news
Phase III trial to study interferon beta therapy in COVID-19 patients initiated
Synairgen's interferon beta therapy is being studied as a potential COVID-19 treatment in a Phase III trial as the first patient is dosed.
news
FDA monitoring impact of SARS-CoV-2 mutations
The FDA has alerted clinical laboratory staff and healthcare providers that it is monitoring the potential impact of SARS-CoV-2 mutations, including the UK variant.
news
Risankizumab trials show higher clinical remission in patients with Crohn’s disease
Two Phase III trials have shown that two doses of risankizumab met the primary endpoints in patients with Crohn's disease.
news
Tocilizumab and sarilumab reduce COVID-19 patient mortality by 8.5 percent, data shows
IL-6 receptor antagonists tocilizumab and sarilumab have a significant impact on COVID-19 patient mortality, a study has shown.
news
Bayer to support development and supply of CVnCoV COVID-19 vaccine
Bayer has signed a collaboration and services agreement with CureVac for the development of CVnCoV, a COVID-19 vaccine currently in late-stage trials.
news
European Commission approves first treatment for peanut allergy
Aimmune Therapeutics' PALFORZIA® has been approved by the European Commission as a treatment for peanut allergy.
news
Oral contraceptive pills protect against ovarian and endometrial cancer, study finds
A study has shown that the use of oral contraceptives gave women a much lower risk of developing both ovarian and endometrial cancer.
news
Phase III study to confirm efficacy of siltuximab as COVID-19 therapy initiated
The SILVAR study is designed to reaffirm the results of the SISCO trial, which showed that siltuximab led to a reduced mortality rate from COVID-19.
news
Oral hormone therapy found to alter metabolome of postmenopausal women
Research has shown oral hormone therapy significantly impacts the metabolome of postmenopausal women, explaining certain disease risks.